Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells

C. Ceresa; E. Giovannetti; J. Voortman; A. Laan; R.J. Honeywell; G. Giaccone; G.J. Peters

doi:https://doi.org/10.1158/1535-7163.MCT-08-0700

Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells

C. Ceresa, E. Giovannetti, J. Voortman, A. Laan, R.J. Honeywell, G. Giaccone, G.J. Peters

Research output: Contribution to journal › Article › Academic › peer-review

17 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1026-1036
Journal	Molecular Cancer Therapeutics
Volume	8
Issue number	5
DOIs	https://doi.org/10.1158/1535-7163.MCT-08-0700
Publication status	Published - 2009

Access to Document

https://doi.org/10.1158/1535-7163.MCT-08-0700

Cite this

@article{f1450a5b1b824a89a309b4c4e056656d,

title = "Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells",

author = "C. Ceresa and E. Giovannetti and J. Voortman and A. Laan and R.J. Honeywell and G. Giaccone and G.J. Peters",

year = "2009",

doi = "https://doi.org/10.1158/1535-7163.MCT-08-0700",

language = "Undefined/Unknown",

volume = "8",

pages = "1026--1036",

journal = "Molecular Cancer Therapeutics",

issn = "1535-7163",

publisher = "American Association for Cancer Research Inc.",

number = "5",

}

TY - JOUR

T1 - Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells

AU - Ceresa, C.

AU - Giovannetti, E.

AU - Voortman, J.

AU - Laan, A.

AU - Honeywell, R.J.

AU - Giaccone, G.

AU - Peters, G.J.

PY - 2009

Y1 - 2009

U2 - https://doi.org/10.1158/1535-7163.MCT-08-0700

DO - https://doi.org/10.1158/1535-7163.MCT-08-0700

M3 - Article

C2 - 19383850

SN - 1535-7163

VL - 8

SP - 1026

EP - 1036

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

IS - 5

ER -